Molecular structure of Amprenavir, CAS Number: 161814-49-9
Amprenavir (CAS 161814-49-9)
See product citations (2)
Alternate Names:
N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic Acid (3S)-Tetrahydro-3-furanyl Ester; 141W94; KVX-478; Agenerase; Prozei
Application:
Amprenavir is a selective HIV protease inhibitor
CAS Number:
161814-49-9
Purity:
≥98%
Molecular Weight:
505.63
Molecular Formula:
C25H35N3O6S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Amprenavir is a human immunodeficiency virus (HIV) protease inhibitor with IC50 of 14.6 ± 12.5 ng/ml for wild-type HIV isolates. Like all HIV protease inhibitors, amprenavir interrupts the maturation phase of the HIV replicative cycle by forming an inhibitor-enzyme complex, which prevents HIV protease from binding with its normal substrates. This compound has an enzyme inhibition constant (Ki = 0.6 nM) that falls within the Ki range of the other protease inhibitors. Amprenavir is an inhibitor of HIV-1 Protease.
Amprenavir (CAS 161814-49-9) References
- Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. | Polli, JW., et al. 1999. Pharm Res. 16: 1206-12. PMID: 10468021
- In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats. | Shibata, N., et al. 2002. J Pharm Pharmacol. 54: 221-9. PMID: 11848286
- Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. | Tran, JQ., et al. 2002. Clin Pharmacol Ther. 72: 615-26. PMID: 12496743
- Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals. | Morse, GD., et al. 2005. Antimicrob Agents Chemother. 49: 3373-81. PMID: 16048950
- Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV. | Wire, MB., et al. 2006. Antimicrob Agents Chemother. 50: 1578-80. PMID: 16569890
- Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus. | Kohli-Pamnani, A., et al. 2006. Ann Allergy Asthma Immunol. 96: 620-3. PMID: 16680935
- Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks. | Okusanya, O., et al. 2007. Antimicrob Agents Chemother. 51: 1822-6. PMID: 17283195
- Different evidence of key amprenavir resistance mutations on the efficacy of darunavir. | Di Biagio, A., et al. 2008. AIDS. 22: 437-8. PMID: 18195574
- Therapeutic amprenavir concentrations in cerebrospinal fluid. | Croteau, D., et al. 2012. Antimicrob Agents Chemother. 56: 1985-9. PMID: 22290964
- Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. | Esposito, V., et al. 2013. J Cell Physiol. 228: 640-5. PMID: 22886568
- Pregnane X receptor mediates dyslipidemia induced by the HIV protease inhibitor amprenavir in mice. | Helsley, RN., et al. 2013. Mol Pharmacol. 83: 1190-9. PMID: 23519392
- Repositioning of amprenavir as a novel extracellular signal-regulated kinase-2 inhibitor and apoptosis inducer in MCF-7 human breast cancer. | Jiang, W., et al. 2017. Int J Oncol. 50: 823-834. PMID: 28197631
- The HIV - 1 protease inhibitor Amprenavir targets Leishmania donovani topoisomerase I and induces oxidative stress-mediated programmed cell death. | Roy, A., et al. 2021. Parasitol Int. 82: 102287. PMID: 33515743
- Insights into effect of the Asp25/Asp25' protonation states on binding of inhibitors Amprenavir and MKP97 to HIV-1 protease using molecular dynamics simulations and MM-GBSA calculations. | Yu, YX., et al. 2021. SAR QSAR Environ Res. 32: 615-641. PMID: 34157882
Inhibitor of:
CHCHD2, CMTM7, HIV-1 p17, HIV-1 p55, HIV-1 Protease, NANP, PRX I, S3-12, and UGT1A6A.Activator of:
ABCC11, and HIV-1 Nef.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Amprenavir, 5 mg | sc-207287 | 5 mg | $217.00 | |||
Amprenavir, 10 mg | sc-207287A | 10 mg | $394.00 |